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Abstract
Background: Valid estimates of health-related quality-of-life (HRQoL) are often difficult to obtain from persons with
Alzheimer’s disease (AD) and family caregiver proxies. To help assess whether the general public can serve as an
alternate source of proxy HRQoL estimates in AD, we examined whether the general public can use vignettes to
discriminate between AD health states.
Methods: We administered a telephone survey to randomly recruited participants from the general public who
were aged 18 years or older. Interviewers read vignettes describing the mild, moderate, and severe AD health states
to the participants, who answered the EQ-5D-5L and Quality of Life-Alzheimer’s Disease (QoL-AD) scales as if they
had AD based on the vignette descriptions. Participants also answered the EQ-5D-5L for their current health states.
We converted EQ-5D-5L responses into health utility scores using Canadian preference weights. We employed the
Wilcoxon signed rank test to examine whether mean health utility scores and mean QoL-AD scores differed
between health states. We used Pearson’s r to assess correlations between health utility and QoL-AD scores.
Results: Forty-eight participants (median age = 53 years; 25 female) completed the telephone interview; health utility
and QoL-AD scores decreased as AD severity increased (p <0.0001). Mean health utility scores were 0.65 (mild), 0.51
(moderate), and 0.25 (severe). Mean QoL-AD scores were 26.7 (mild), 23.0 (moderate), and 17.4 (severe). The correlations
between health utility and QoL-AD scores were moderate to strong (r≥ 0.62).
Conclusions: Using the vignettes, the general public provided HRQoL estimates that discriminated between the three
AD health states. This finding suggests the general public may be a promising source of proxy HRQoL estimates in
place of persons with AD.
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Background
The World Health Organization defines health-related
quality-of-life (HRQoL) as an “individual’s perception of
their position in life in the context of the culture and
value systems in which they live and in relation to their
goals, expectations, standards and concerns” [1]. In
Alzheimer’s disease (AD), HRQoL is typically measured
with validated scales such as the EuroQoL Group’s
utility-based EQ-5D-5L scale [2] and the Quality-of-life –
Alzheimer’s Disease (QoL-AD) scale [3]. Individuals’
responses to utility-based instruments such as the EQ-5D-
5L are used to calculate health utility scores, while re-
sponses to the QoL-AD are used to calculate numerical
scores that quantify HRQoL.
Health utility scores are used to compute quality-
adjusted life-years (QALYs) [4] for economic evaluations
of new health technologies. Economic evaluations are
becoming an increasingly important component of pub-
lic health insurance coverage decisions in AD and other
disease areas. In the United Kingdom (UK), policy
makers used an economic evaluation to recommend
delisting coverage of cholinesterase inhibitors for per-
sons with mild AD [5].* Correspondence: moremus@uwaterloo.ca1School of Public Health and Health Systems, University of Waterloo, 200
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Due to cognitive impairment, many persons with AD
may be unable to complete HRQoL scales, especially as
the disease progresses and cognitive function worsens
[6, 7]. Although some persons with AD might be capable
of answering the question “How do you feel now?” [8],
the verbal or non-verbal responses to this question can-
not be converted into health utility scores or QALYs.
Researchers frequently ask family caregivers to provide
proxy HRQoL estimates in place of their loved ones with
AD. However, family caregivers may underestimate their
loved ones’ HRQoL because they integrate their own life
experiences (e.g., the burden and stress of caregiving)
into the proxy assessments [9–15].
Given the challenges of obtaining valid HRQoL esti-
mates from persons with AD or their caregiver proxies,
we launched a research program to investigate whether
the general public can serve as an alternate source of
valid proxy HRQoL estimates in AD. The first step in
this research program was to examine whether the general
public could provide HRQoL estimates that discriminate
between mild, moderate, and severe AD. This paper re-
ports the findings of this first step.
Methods
Vignettes
Most members of the general public are unlikely to have
first-hand knowledge of AD. To provide a frame of refer-
ence, we developed three vignettes that describe what
life is like for an individual who lives with mild, moder-
ate, or severe AD (Additional file 1). We formulated the
vignettes through content analysis [16] of feedback from
focus groups composed of persons with AD, family care-
givers, and physicians who specialize in treating AD.
Members of the general public then read each vignette
and answered the EQ-5D-5L and QoL-AD as if they had
AD based on the vignette descriptions.
Participant recruitment and interview administration
We used published telephone numbers and random digit
dialling to recruit a general public sample from the
Greater Toronto Area, Niagara Region, and City of
Hamilton (Ontario, Canada). We included individuals
aged 18 years or older who could communicate in English.
Participants were randomly allocated to hear the mild,
moderate, and severe vignettes in one of the six possible
orders of vignettes during a telephone interview.
The telephone interviews followed a fixed script ad-
ministered using computer-assisted telephone interview
software (Telephone Survey Software – Voxco Canada,
Montréal, QC). In the first stage of the interview, the in-
terviewers asked participants for their age, sex, highest
education level, and annual household income. Partici-
pants also indicated whether any of their family members
or close friends had been diagnosed with AD. Participants
rated their own HRQoL on the interview day by complet-
ing the EQ-5D-5L. In the second stage of the interview,
the interviewers read the vignettes to participants. After
hearing each vignette, participants completed the EQ-5D-
5L and the Qol-AD as if they had AD according the de-
scription just heard.
Health-related Quality-of-life Scales
The EQ-5D-5L consists of five questions about mobility,
self-care, usual activities, pain/discomfort, and anxiety/de-
pression [2]. Each question has five response levels: no im-
pairment (level 1), slight impairment (level 2), moderate
impairment (level 3), severe impairment (level 4), and ex-
treme impairment (level 5). We used a Canadian-based al-
gorithm [17] to transform each participant’s EQ-5D-5L
responses into a single health utility score between 0 and
1. A score of 0 represents a health state equivalent to be-
ing dead and a score of 1 represents perfect health [4].
The QoL-AD measures the quality-of-life of persons
with AD [3]. Quality-of-life is rated on each of 13 domains
and response options range from ‘poor’ (score = 1) to
‘excellent’ (score = 4). The overall scale score ranges
from 13 to 52 (higher scores indicate better quality-
of-life). Higher QoL-AD scores are correlated with
less behavioural impairment, better psychological status,
less impairment on physical function, and better interper-
sonal environments [3].
Statistical analysis
We employed the Wilcoxon signed rank test to examine
whether the differences in health utility scores between
vignettes were statistically significant. We used the same
test to investigate whether the differences in QoL-AD
scores between vignettes were statistically significant.
We employed Pearson’s r to assess the correlation between
each vignette’s health utility and QoL-AD scores. The ana-
lyses were implemented in SPSS v22 (IBM Corporation,
Armonk, NY).
For sample size, available resources allowed us to plan
on recruiting 48 participants. To determine the smallest
differences in score between vignettes that we could de-
tect with this number, we undertook a sample size calcu-
lation based on the paired t-test, setting α = 0.05 and 1-ß
(power) = 0.84 (equivalent to 80 % power after adjusting
for the lower efficiency of the Wilcoxon signed rank test
compared to the paired t-test [18]). We used data from
previous research [19] to compute standard deviations
for mean differences in health utility and QoL-AD scores
across AD health states (i.e., 0.04 [health utility], 1.47
[QoL-AD]). The calculations showed that 48 participants
would allow us to detect differences in health utility
score of at least 0.02 and differences in QoL-AD score
of at least 0.64. Thus, we would be able to detect differ-
ences in health utility score that were smaller than the
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minimum important difference of 0.074 [20] (the litera-
ture does not report a minimum important difference
for the QoL-AD). For the correlation analysis, 48 partici-
pants would permit us to detect at least a ‘fair’ correl-
ation (r ≥ 0.4) between health utility and QoL-AD scores
at α = 0.05 and 1-ß = 0.8.
Prior to commencing the study, we obtained approval
from the Hamilton Integrated Research Ethics Board
(reference number 13-271). All participants gave oral




The median age of the 48 participants was 53 years and
25 were female (Table 1). The majority of participants
(n = 34) were college or university graduates and most
(n = 28) reported annual household incomes of at least
$60,000. Twenty-three participants said they knew a
family member or close friend with AD. The mean health
utility score for the participants’ current health state was
0.87 (95 % confidence interval [CI]: 0.83 to 0.91).
Participants’ responses to the EQ-5D-5L shifted from
less to more problems as health states declined (Table 2).
For participants’ current health state, most responses
were concentrated in the ‘no problem’ response cat-
egory. For mild AD, most responses indicated ‘no’ or
‘slight’ problems; for moderate AD, the bulk of responses
reflected ‘slight’ or ‘moderate’ problems. For severe AD,
the majority of participants answered ‘severe’ or ‘ex-
treme’ problems. These trends were less pronounced for
the ‘pain/discomfort’ question relative to the other four
Table 1 Sample characteristics
Characteristic Data





Less than high schoola 2
High school graduatea 8
Technical or trade school graduatea 4
College graduate 21
University graduate (Bachelor, Master’s,
Doctorate)
13







Family member/close friend diagnosed with AD – n
Yes 23
No 25
Health utility index score – mean (95 % CI) 0.87 (0.83–0.91)
AD Alzheimer’s disease, CI confidence interval, n number of participants,
y years
aCategories combined with one another for regression analysis
bCanadian dollars
cCategories combined with one another for regression analysis









No problems 38 13 8 0
Slight problems 6 21 13 6
Moderate problems 3 13 21 17
Severe problems 1 0 4 17
Unable to walk 0 1 2 8
Self-care – n
No problems 45 2 3 1
Slight problems 2 24 8 0
Moderate problems 1 16 27 11
Severe problems 0 5 8 18
Unable to wash/dress 0 1 2 18
Usual Activities – n
No problems 41 3 0 0
Slight problems 4 12 5 2
Moderate problems 2 27 26 8
Severe problems 0 5 14 23
Unable to do 1 1 3 15
Pain/Discomfort – n
No pain/discomfort 22 19 15 7
Slight pain/discomfort 21 20 13 13
Moderate pain/discomfort 4 9 18 16
Severe pain/discomfort 1 0 1 11
Extreme pain/discomfort 0 0 1 1
Anxiety/Depression – n
Not anxious/depressed 32 4 2 1
Slightly anxious/depressed 13 14 6 6
Moderately anxious/depressed 2 18 19 11
Severely anxious/depressed 1 3 17 15
Extremely anxious/depressed 0 1 4 14
Refused to answer 0 1 0 1
AD Alzheimer’s disease, n number of participants
aParticipants’ current health state on the day of the interview
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questions, probably because the vignettes did not de-
scribe pain-related symptoms.
Given five questions and five response categories, the
EQ-5D-5L contains 3125 possible response combina-
tions. In our study, the participants reported 15 distinct
combinations for their current health state, 38 for mild
AD, 43 for moderate AD, and 42 for severe AD. Sixteen
participants reported that their current health state
entailed no problems on all five questions, while a fur-
ther 15 participants reported no problems on four ques-
tions and slight problems on one question. None of the
participants reported no problems on all five questions
for any of the AD health states.
Health-related quality-of-life estimates for Alzheimer’s
disease
Participants’ HRQoL estimates were inversely related to
disease severity (Table 3). Mean health utility scores
were 0.65 (mild), 0.51 (moderate), and 0.25 (severe).
Mean QoL-AD scores were 26.7 (mild), 23.0 (moderate),
and 17.4 (severe). All of the scores were statistically sig-
nificantly different from one another (p <0.0001). On
average, participants’ health utility scores for their own
current health state were higher than their utility scores
for mild AD (mean difference: 0.23; p <0.0001).
The correlations between health utility and QoL-
AD scores were moderate to strong (Fig. 1): r = 0.62
(p <0.0001) for the mild AD vignette, r = 0.69 (p <0.0001)
for the moderate vignette, and r = 0.77 (p <0.0001) for the
severe vignette.
Discussion
The study participants, all members of the general pub-
lic, provided HRQoL estimates that discriminated be-
tween the mild, moderate, and severe AD health states.
Participants reported more problems on the EQ-5D-5L
Table 3 Health-related quality-of-life estimates for Alzheimer’s
disease





Difference: Mild - Moderate 0.15c 3.7c
Difference: Mild - Severe 0.41c 9.3c
Difference: Moderate - Severe 0.27c 5.6c
CI confidence interval, QoL-AD Quality-of-life – Alzheimer’s Disease
aEQ-5D-5L responses were converted into health utility scores (0 = death;
1 = perfect health); means and mean differences were rounded to two
decimal places
bScore range 13 to 52: lower scores indicate poorer
health-related quality-of-life
cp <0.0001
Fig. 1 Correlations between general public health utility scores and
QoL-AD scores. r: Pearson correlation coefficient; QoL-AD: Quality-of-
life – Alzheimer’s Disease scale
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as they responded to vignettes describing successively
worsening AD health states. Also, most participants pro-
vided unique EQ-5D-5L response combinations for each
AD health state, which suggests that the vignettes were
not leading individuals into a narrow band of responses.
Health utility scores and QoL-AD scores declined as
health states worsened. Correlations between the EQ-
5D-5L and QoL-AD were moderately strong, which
shows that participants’ responses were robust across
different measurement instruments.
Only two other published AD studies have examined
the topic that we present in this paper. In our earlier re-
search, we conducted a vignette-based study and elicited
HRQoL estimates from a single-city convenience sample
of 100 members of the general public [19]. Although we
found an inverse relation between participants’ HRQoL
estimates (EQ-5D-5L and QoL-AD) and the severity of
the AD, each participant provided HRQoL estimates for a
single health state, rather than for all three health states.
Also, we wrote the vignettes featured in the earlier study
without input from other stakeholders because the intent
of this project was to conduct an initial exploration of
whether the general public can understand and appreciate
the intricacies of a syndrome such as AD. Our current
work replicates these earlier findings using a different set
of vignettes, which demonstrates that the general public’s
HRQoL estimates are not tied to the specific vignettes
used in a study. Furthermore, since the participants in the
current study provided HRQoL estimates for all three
health states, random allocation to the sequence in which
the health states were presented was shown to control for
ordering effects.
In the second published AD study [21], 78 members of
the general public in the UK used the time trade-off task
[22] to value eight of 1024 possible health states from
the DEMQOL-U and eight of 256 possible health states
from the DEMQOL-U-Proxy. The DEMQOL instru-
ments [23] measure HRQoL in dementia, with the
DEMQOL-U intended to be completed by persons with
AD and the DEMQOL-U-Proxy intended to be com-
pleted by caregivers. While participants’ health utility
scores tended to decrease as DEMQOL health states
worsened, the researchers did not tell participants that
they were rating health states for dementia. Indeed, three
of the domains on the DEMQOL-U (i.e., cheerfulness,
frustration, loneliness) and three of the domains on the
DEMQOL-U-Proxy (i.e., liveliness, keeping oneself look-
ing nice, frustration) have no obvious links to dementia.
Therefore, the UK participants’ HRQoL estimates may
have reflected their own health states on the day of the
study interview, rather than any health states related to
dementia. In our study, the interviewers told participants
that they were estimating HRQoL for AD health states,
which is comensurate with methods guidance [24].
Researchers in other illness domains have found that
members of the general public can discriminate between
different health states (i.e., hepatic encephalopathy [25].
non-small cell lung cancer [26], rheumatoid arthritis [27])
after being presented with vignettes to describe the health
states. In another study [28], the researchers used data
from randomized controlled trials to develop ‘before-after’
vignettes for each of five health conditions (i.e., depression,
osteoarthritis, insomnia, chronic obstructive pulmonary
disorder, Crohn’s disease). The ‘before’ vignettes described
the symptoms for each condition prior to treatment; the
‘after’ vignettes described a less severe set of symptoms for
each condition following treatment. Post-treatment utilities
were statistically significantly lower than pre-treatment
utilities for all of the health conditions except insomnia.
Implications of the research
Our current and past work [19] has consistently shown
that members of the general public can discriminate be-
tween the mild, moderate, and severe AD health states.
The next step is to establish whether the general public
can provide valid proxy HRQoL estimates in place of per-
sons with AD. To investigate this issue, we plan to compare
the general public’s proxy HRQoL estimates to estimates
obtained directly from persons with AD. A challenge will
be to recruit persons with AD who are cognitively capable
of answering the EQ-5D-5L or QoL-AD.
The use of the general public instead of caregivers to
measure HRQoL can have practical advantages for re-
searchers. General public samples are far more accessible
than caregiver samples. Members of the general public can
be recruited through numerous vehicles, including ongoing
population-level studies (e.g., Canadian Longitudinal Study
on Aging [CLSA] [29]) or telephone polling surveys.
AD caregivers would be a challenge to recruit through ei-
ther vehicle. Population studies may not ask participants
about their caregiver status, nor may they be designed to
recruit caregivers. Surveys conducted through polling firms
would require screening questions to identify caregivers
from among the people telephoned and invited to partici-
pate. The number of telephone calls required to recruit a
sufficient number of caregivers could be substantial enough
to exceed the resource capacity of many researchers. Alter-
natively, researchers could attempt to build rosters of care-
givers in collaboration with medical practices, advocacy
organizations, support groups, or long-term care facilities.
However, this approach takes time and is compounded by
the fact that recruitment partners do not always prioritize
research activities.
If we find the general public can provide valid proxy
HRQoL estimates in AD, then these estimates can be
employed in economic evaluations to calculate QALYs
and help policy makers decide if public health insurers
should reimburse new AD treatments. Due to the
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relative ease of randomly recruiting general public samples
and adminstering vignettes along with the EQ-5D-5L and
QoL-AD, researchers will be able to collect data from
samples based in the jurisdictions to which policy deci-
sions will be applied. The greater difficulty of recruiting
caregivers into research studies could otherwise lead ana-
lysts to use HRQoL data collected from other jurisdic-
tions, perhaps simply as a matter of expediency given the
time-sensitive nature of reimbursement decision making.
Such data may not be readily transferable across jurisdic-
tions because of socio-demographic differences between
populations or differences in healthcare systems.
Limitations
The study sample was over-representative of persons
with a post-secondary education and half of the partici-
pants were over 53 years of age. More educated individ-
uals might possess a greater capacity to distinguish
between the nuances of the vignettes. Persons in middle
or old age might be more aware of AD because age is
one of the strongest risk factors for the disease. Less ed-
ucated and younger samples may have a more difficult
time of discriminating between AD health states.
Vignettes represent abstractions of real-life phenomena
and do not capture the entire essence of living with disease.
To enhance the validity of the vignettes employed in this
study, we used input from stakeholders who experience
AD on a daily basis to craft the content of the vignettes.
We also point out that vignettes are used extensively in
AD research to examine diverse samples’ attitudes to a
multiplicity of issues such as therapeutic interventions and
HRQoL [30]. Examples of diverse samples used in other
vignette-based studies include persons with AD, caregivers,
healthcare professionals, and members of the general pub-
lic. Vignettes have also been used to examine people’s emo-
tional reactions to AD, as well as ethno-cultural and social
differences in their attitudes to the disease [30].
Conclusions
Members of the general public can discriminate between
AD health states. This finding suggests the general pub-
lic might be a source of valid proxy HRQoL estimates in
place of persons with AD. Further assessment of the
general public’s potential to serve as a proxy will require
comparing the general public’s HRQoL estimates to esti-
mates obtained directly from persons with AD.
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